Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

A Dual Inhibitor Treatment for RA?

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Zeng X, Wu C, Hu J, et al. Head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: Interim results from a phase 2a study (abs LB0001). Ann Rheum Dis. 2023;82(suppl 1):200.
  2. Schlapbach C, Conrad C. TYK-ing all the boxes in psoriasis. J Allergy Clin Immunol. 2022 Jun;149(6):1936–1939.
  3. News release: Highlightll Pharmaceutical TLL-018 achieved breakthrough results in a phase ii trial for rheumatoid arthritis. Hangzhou Highlightll Pharmaceutical Co. Ltd. 2023 Jan 23.

Related Articles

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…